RecruitingNot Applicable

Three Types of Nucleotide/Nucleoside Analogues Treatment in HBV Related ACLF

China150 participantsStarted 2019-02-21

Plain-language summary

This study is to investigate the clinical efficacy of three types of nucleotide/nucleoside analogues in treatment of HBV-related acute-on-chronic liver failure.

Who can participate

Age range12 Years – 65 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Positive hepatitis b surface antigen or hepatitis b virus DNA \> 0.5 year;
✓. Age from 12 to 65 years old;
✓. Serum total bilirubin level \> 10 times upper limit of normal;
✓. Prothrombin time activity \< 40% or prothrombin time international ratio \> 1.5；
✓. Do not receive nucleotide/nucleoside analogues treatment in the past half year.

Exclusion criteria

✕. Other active liver diseases;
✕. Hepatocellular carcinoma or other malignancy;
✕. Pregnancy or lactation;
✕. Human immunodeficiency virus infection or congenital immune deficiency diseases;
✕. Severe diabetes, autoimmune diseases;
✕. Other important organ dysfunctions;
✕. Using glucocorticoid;
✕. Patients can not follow-up;

What they're measuring

Survival rate in the follow-up

Timeframe: 144 week

Trial details

NCT IDNCT03920618

SponsorThird Affiliated Hospital, Sun Yat-Sen University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2024-12-31

Contact for this trial

Wenxiong Xu, Doctor

+8613760783281 xwx1983@163.com

View on ClinicalTrials.gov More Hepatitis B trials